title: High patient compliance with nicacin/laropiprant in large clinical trial: interim safety and tolerability results from HPS-2 THRIVE study released at 2012 ESC congress: drug trends in cardiology.
mesh_terms: D062067:Chemical Safety; D002681:China; D008076:Cholesterol, HDL / Q000378:metabolism*; D003324:Coronary Artery Disease / Q000188:drug therapy*; D005060:Europe; D005500:Follow-Up Studies; D006801:Humans; D007211:Indoles / Q000008:administration & dosage* / Q000009:adverse effects; D050356:Lipid Metabolism / Q000187:drug effects; D009135:Muscular Diseases / Q000209:etiology; D009525:Niacin / Q000008:administration & dosage* / Q000009:adverse effects; D010349:Patient Compliance; D016032:Randomized Controlled Trials as Topic
chemical_list: D008076:Cholesterol, HDL; D007211:Indoles; C518174:MK-0524; D009525:Niacin